TABLE 4.

Clinical outcomes for patients with bloodstream infections caused by AmpC β- lactamase-producing K. pneumoniae isolates versus those caused by TEM- or SHV-related ESBL-producing K. pneumoniae isolates

OutcomeNo. (%) of patientsP
AmpC group (n = 27)ESBL group (n = 25)
Initial treatment failure14 (51.9)14 (56)0.764
Death at 7 days4 (14.8)6 (24)0.492
Death at 30 days8 (29.6)7 (28)0.897